Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease. The increasing incidence of transthyretin amyloid cardiomyopathy (ATTR-CM) among the aging population is expected to boost the transthyretin amyloid cardiomyopathy (ATTR-CM) market growth. For instance, according to an article published by the World Heart Federation in August 2019, wild- form of transthyretin amyloid cardiomyopathy (ATTR-CM) is a more common type and usually affects men after the age of 60, and hereditary transthyretin amyloidosis (hATTR) occurs in people in their 50s and 60s.
The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is estimated to be valued at US$ 748.80 million in 2020 and is expected to exhibit a CAGR of 31.1% during the forecast period (2020-2027).
Figure 1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), by Region, 2020
-treatment-market-fig-1.png "Transthyretin Amyloid Cardiomyopathy Treatment | CMI")
Ongoing research and development activities are expected to propel growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Major players in the market are focused on research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment, which is expected to boost the market growth during the forecast period. For instance, in January 2020, Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., collaboratively initiated CARDIO-TTRansform Phase III cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
However, lack of diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by the Amyloidosis Foundation, in 2016, among the two type of transthyretin amyloid cardiomyopathy (ATTR-CM), wild type transthyretin amyloidosis (wtATTR) is difficult to diagnose than hereditary transthyretin amyloidosis (hATTR) as there is no family history or genetic marker for the disease.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 748.80 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 31.1% | 2027 Value Projection: | US$ 4,984.58 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), by Type 2020
-treatment-market-fig-2.png "Transthyretin Amyloid Cardiomyopathy Treatment | CMI")
Ongoing clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM) in North America are expected to boost the market growth.
North America is expected to hold dominant position in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market owing to the ongoing clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM) in the region. For instance, in November 2020, Intellia Therapeutics, Inc. announced that the first patient has been treated with NTLA-2001, CRISPR/Cas9 technology, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR).
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries have placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market during the forecast period.
Key Players
Major players operating in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. among others.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common type of amyloidosis, which affects the heart, causing heart muscles to stiffen and eventually lead to heart failure. ATTR-CM often causes symptoms of heart failure, such as fatigue, shortness of breath and peripheral edema, and other symptoms related to buildup of amyloid fibrils in the body. There are two forms of transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). This disease is often diagnosed only after symptoms have become severe.
Market Dynamics
Rising incidence of transthyretin amyloid cardiomyopathy is expected to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in December 2019, reports the study of the Japan Medical Data Vision (MDV), which was a hospital based database from January 2010 to September 2018 to estimate the number of currently diagnosed ATTR-CM patients. This study reports data of over 9 years of study which included 3255 patients (155.8 per million adult patients in the MDV database) to 3992 patients (191.1 per million) diagnoses of wild type transthyretin amyloidosis (wtATTR).
However, lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by Amyloidosis. Amyloidosis Foundation in 2016, awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) is low among the general public as well as healthcare professionals and therefore, this condition often is unnoticed.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients